

Publication on regulated agreements
pursuant to Article L.22-10-13 of the French Commercial Code

CONCLUSION OF REGULATED AGREEMENTS WITH SANOFI
(approval by the Board of Directors held on February 28, 2024)

- **Amendment #2 to the Global Manufacturing & Supply Agreement (“GMSA”)**
 - Parties: Euroapi France (Euroapi’s 100% subsidiary) and Sanofi Winthrop Industrie (Sanofi’s 100% subsidiary)
 - Purpose of the Agreement: Improvement of the payment terms, cancellation of Performance clause for 2023, Price increases of 5 APIs, Positive adjustments of price and early Take or Pay volume for one API, Amendment of the Raw Material Pass Through, Global Price Volume Corridor revised, Customer Service Level revised and Update of the list of Exclusive Supply Products by Territories
 - Duration: expiration of the term 2027
 - Financial impact: € 4 Million in 2023 financial statements
 - Interest of the regulated agreement for Euroapi: cash flow improvement, avoidance of unforeseen costs and positive impact on revenues.

- **Side letter #1 to the Reverse Manufacturing and Supply Agreement Francopia**
 - Parties: Francopia (Euroapi’s 100% subsidiary) and Sanofi Winthrop Industrie (Sanofi’s 100% subsidiary)
 - Purpose of the Agreement: Cancellation of the Performance Clause, Cancellation of target for titration of APIs, Cancellation of the Minimum Yearly Quantity of APIs
 - Duration: expiration of the term in 2027
 - Financial impact: N/A
 - Interest of the regulated agreement for Euroapi: less pressure in terms of timing and avoidance of penalties linked to a small increase in volume not aligned with the previous target. The cancellation of the performance clause under this agreement is mirroring the cancellation of the performance clause under above mentioned Amendment° 2 ; as a whole the balance is financially positive.

- **Side letter #2 to the Reverse Manufacturing and Supply Agreement (“RMSA”) Francopia**
 - Parties: Francopia (Euroapi’s 100% subsidiary) and Sanofi Winthrop Industrie (Sanofi’s 100% subsidiary)
 - Purpose of the Agreement: Renunciation by Sanofi to a specific claim
 - Duration: N/A
 - Financial impact: € 1,4Million in 2023
 - Interest of the regulated agreement for Euroapi: avoidance of extra costs and penalties

- **Side letter related to the GMSA and the Reverse Manufacturing and Supply Agreement (BI Products)**
 - Parties: Euroapi France (Euroapi’s 100% subsidiary) and Sanofi Winthrop Industrie (Sanofi’s 100% subsidiary)

- Purpose of the Agreement: Payment by Sanofi of an incentive for the transfer of a specific API
 - Duration: NA – payment of € 2M intervened on December 31, 2023
 - Financial conditions: remaining payment of € 2,5Million in 2024
 - Interest of the regulated agreement for Euroapi: avoidance of extra costs and improvement of the securization of production of APIs
- **Memorandum of Understanding (MOU) related to the GMSA**
 - Parties: Euroapi France (Euroapi's 100% subsidiary) and Sanofi Winthrop Industrie (Sanofi's 100% subsidiary)
 - Purpose of the Agreement:
 - In relation to the GMSA: Compensation for substantial market demand decrease, Purchase by Sanofi of the remaining APIs and intermediates inventory of an API, Payment by Sanofi of a lumpsum for the term of the GMSA for capacity extension project and payment by Sanofi of an incentive for specific APIs
 - In relation to the RMSA (B12): Payment by Sanofi of an incentive for a B12 derivative salts transfer
 - Duration:
 - In relation to the GMSA: Term in 2027
 - In relation to the RMSA (B12): Term on December 31, 2024
 - Financial impact: € 40 Million (€ 37 Million in 2024 and € 3 Million in 2025)
 - Interest of the regulated agreement for Euroapi: avoidance of extra costs upon APIs transfer, compensation of volumes decrease

CONCLUSION OF A REGULATED AGREEMENT WITH CECILE DUSSART
(approval by the Board of Directors held on October 25, 2023)

- Parties: Euroapi and Cécile Dussart (independent director)
- Purpose of the Agreement: Mrs. Cécile Dussart assists the new Chief Operating Officer in its training on the Company's operations, procedures and corporate culture. In this role, Mrs. Cécile Dussart will not participate or be involved in any decision relating to the proper running of the Company
- Duration: 6 months
- Financial conditions: Mrs. Cécile Dussart to (i) be compensated at the rate of €5,000 (exclusive of VAT) per month in consideration of the services rendered pursuant to the Assignment, and (ii) be reimbursed of all reasonable and necessary travel expenses in connection with the mission, in accordance with the Company's expense and travel reimbursement policy
- Interest of the regulated agreement for Euroapi: facilitate the induction and integration process for the Company's new Chief Operation Officer